Alector, Inc.
corporate_fare Company Profile
Alector, Inc. (NASDAQ:ALEC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for ALEC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for ALEC spans 8-K, 424B5, 10-Q, S-3.
Recent high-impact activity:
- Alector Posts $124.6M Q3 Net Income on GSK Deferred Revenue; Cash Runway to 2H 2029
- Alector Swings to $124.6M Q3 Profit on GSK Deferred Revenue, Cash Runway to 2H 2029
- Alector Prices $75M Offering at 7.3% Premium to Raise Cash Into 2027
- Alector Licenses AL050 to Genentech for $100M Upfront, Extends Cash Runway into 2029
- Alector Lands $100M Upfront, Up to $1.17B in Milestones from Genentech for Brain-Penetrant GCase Therapy
Financial Snapshot
Short Interest & Short Volume
3.62 days to coverFINRA reported short interest of 8,393,562 shares in ALEC as of the October 30, 2026 settlement, a 18.1% decrease from the prior period — about 3.6 days to cover at its recent average daily volume. On November 20, 2026, 54.4% of ALEC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ALEC, detected from its recent SEC filings · based on capital-structure filings through 2026-10-16.
36.6M Shares Priced at $2.05 · Net Proceeds About $70.2M
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →